X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare GSK Pharma with ALEMBIC LTD - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs ALEMBIC LTD - Comparison Results

GSK PHARMA    Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

ALEMBIC LTD 
   Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA ALEMBIC LTD GSK PHARMA/
ALEMBIC LTD
 
P/E (TTM) x 59.2 75.7 78.2% View Chart
P/BV x 11.6 2.8 413.2% View Chart
Dividend Yield % 2.1 0.4 532.0%  

Financials

 GSK PHARMA   ALEMBIC LTD
EQUITY SHARE DATA
    GSK PHARMA
Mar-16
ALEMBIC LTD
Mar-16
GSK PHARMA/
ALEMBIC LTD
5-Yr Chart
Click to enlarge
High Rs3,85053 7,291.7%   
Low Rs2,96629 10,121.7%   
Sales per share (Unadj.) Rs332.34.7 7,041.3%  
Earnings per share (Unadj.) Rs44.38.8 504.9%  
Cash flow per share (Unadj.) Rs47.29.0 524.5%  
Dividends per share (Unadj.) Rs50.000.15 33,333.3%  
Dividend yield (eoy) %1.50.4 401.5%  
Book value per share (Unadj.) Rs202.727.7 731.2%  
Shares outstanding (eoy) m84.70267.03 31.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x10.38.7 117.9%   
Avg P/E ratio x76.94.7 1,644.2%  
P/CF ratio (eoy) x72.24.6 1,582.7%  
Price / Book Value ratio x16.81.5 1,135.4%  
Dividend payout %112.91.7 6,602.0%   
Avg Mkt Cap Rs m288,64310,962 2,633.2%   
No. of employees `0004.6NA-   
Total wages/salary Rs m4,434238 1,863.0%   
Avg. sales/employee Rs Th6,104.5NM-  
Avg. wages/employee Rs Th961.6NM-  
Avg. net profit/employee Rs Th813.7NM-  
INCOME DATA
Net Sales Rs m28,1481,260 2,233.4%  
Other income Rs m1,218264 461.8%   
Total revenues Rs m29,3661,524 1,926.8%   
Gross profit Rs m4,77483 5,765.4%  
Depreciation Rs m24861 403.9%   
Interest Rs m00 0.0%   
Profit before tax Rs m5,744285 2,016.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m02,096 0.0%   
Extraordinary Inc (Exp) Rs m26-32 -80.7%   
Tax Rs m2,0186 33,082.0%   
Profit after tax Rs m3,7522,343 160.2%  
Gross profit margin %17.06.6 258.1%  
Effective tax rate %35.12.1 1,640.9%   
Net profit margin %13.3185.9 7.2%  
BALANCE SHEET DATA
Current assets Rs m21,4621,689 1,270.8%   
Current liabilities Rs m10,536486 2,167.1%   
Net working cap to sales %38.895.4 40.7%  
Current ratio x2.03.5 58.6%  
Inventory Days Days68217 31.2%  
Debtors Days Days1681 20.3%  
Net fixed assets Rs m4,7171,624 290.4%   
Share capital Rs m847534 158.6%   
"Free" reserves Rs m16,3085,960 273.6%   
Net worth Rs m17,1717,404 231.9%   
Long term debt Rs m16104 15.3%   
Total assets Rs m30,6208,010 382.3%  
Interest coverage xNM950.7-  
Debt to equity ratio x00 6.6%  
Sales to assets ratio x0.90.2 584.3%   
Return on assets %12.329.3 41.9%  
Return on equity %21.931.6 69.1%  
Return on capital %33.631.3 107.3%  
Exports to sales %02.9 0.5%   
Imports to sales %15.128.9 52.2%   
Exports (fob) Rs m437 10.8%   
Imports (cif) Rs m4,237364 1,165.0%   
Fx inflow Rs m51937 1,398.9%   
Fx outflow Rs m8,320365 2,279.7%   
Net fx Rs m-7,801-328 2,379.4%   
CASH FLOW
From Operations Rs m1,386346 400.9%  
From Investments Rs m5,010-48 -10,524.4%  
From Financial Activity Rs m-6,383-301 2,120.7%  
Net Cashflow Rs m12-3 -393.3%  

Share Holding

Indian Promoters % 0.0 64.0 -  
Foreign collaborators % 50.7 0.0 -  
Indian inst/Mut Fund % 10.2 0.2 5,100.0%  
FIIs % 23.8 9.7 245.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 26.1 59.0%  
Shareholders   102,036 54,701 186.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   NATCO PHARMA  PANACEA BIOTECH  WOCKHARDT LTD.  PFIZER  ALKEM LABORATORIES  

Compare GSK PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Flat Note; Dr Reddy's & Lupin Surge over 2%(Closing)

Indian share markets continued to trade just above the dotted line in the afternoon session in a lackluster day of trading. At the closing bell, the BSE Sensex closed higher by 33 points.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Aug 22, 2017 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE GSK PHARMA WITH

MARKET STATS